Monte Rosa Therapeutics, Inc. Amortization of Intangible Assets
Monte Rosa Therapeutics, Inc. (GLUE) reported Amortization of Intangible Assets of $708.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $708.00K, a 15.12% increase year-over-year.
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $643.00K, a 12.02% increase year-over-year.
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $673.00K, a 31.70% increase year-over-year.
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $637.00K, a 10.21% increase year-over-year.
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for fiscal 2025 was $2.50M, a 19.05% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for fiscal 2024 was $2.10M, a 0.00% change from fiscal 2023.
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for fiscal 2023 was $2.10M, a 16.00% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. amortization of intangible assets for fiscal 2022 was $2.50M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $708.00K 10-Q · filed 2026-08-06 | $1.35M 10-Q · filed 2026-08-06 | $2.02M derived: sum of 3 quarters · filed 2026-08-06 | $2.66M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $643.00K 10-Q · filed 2026-05-07 | $1.32M derived: sum of 2 quarters · filed 2026-05-07 | $1.95M derived: sum of 3 quarters · filed 2026-05-07 | $2.57M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.31M derived: sum of 2 quarters · filed 2026-03-17 | $1.93M derived: sum of 3 quarters · filed 2026-08-06 | $2.50M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $637.00K 10-Q · filed 2025-11-06 | $1.25M derived: sum of 2 quarters · filed 2026-08-06 | $1.83M 10-Q · filed 2025-11-06 | $2.34M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $615.00K 10-Q · filed 2026-08-06 | $1.19M 10-Q · filed 2026-08-06 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $2.28M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $574.00K 10-Q · filed 2026-05-07 | $600.00K 10-Q · filed 2025-05-08 | $1.08M derived: sum of 2 quarters · filed 2026-05-07 | $1.66M derived: sum of 3 quarters · filed 2026-05-07 | $1.87M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $511.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.09M derived: sum of 2 quarters · filed 2026-03-17 | $1.30M derived: sum of 3 quarters · filed 2026-03-17 | $2.10M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | $578.00K 10-Q · filed 2025-11-06 | $789.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.59M 10-Q · filed 2025-11-06 | $1.60M 10-Q · filed 2024-11-07 | $1.69M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $211.00K 10-Q · filed 2025-08-07 | $1.01M 10-Q · filed 2025-08-07 | $1.00M 10-Q · filed 2024-08-08 | $1.11M derived: sum of 3 quarters · filed 2025-08-07 | $1.61M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $800.00K 10-Q · filed 2025-05-08 | $900.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.40M derived: sum of 3 quarters · filed 2025-05-08 | $2.10M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $600.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.30M derived: sum of 3 quarters · filed 2025-03-20 | $2.10M 10-K · filed 2025-03-20 | $2.50M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.20M derived: sum of 2 quarters · filed 2024-11-07 | $2.00M 10-Q · filed 2024-11-07 | $2.10M derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2023-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.50M 10-Q · filed 2024-08-08 | $1.60M derived: sum of 3 quarters · filed 2025-03-20 | $2.60M derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2023-03-31 | $800.00K 10-Q · filed 2024-05-09 | $900.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.90M derived: sum of 3 quarters · filed 2025-03-20 | $2.90M derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.10M derived: sum of 2 quarters · filed 2025-03-20 | $2.10M derived: sum of 3 quarters · filed 2025-03-20 | $2.50M 10-K · filed 2025-03-20 | $3.30M 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.00M derived: sum of 2 quarters · filed 2023-11-09 | $2.40M 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.40M 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | $400.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |